Nav: Home

Impeding white blood cells in antiphospholipid syndrome reduced blood clots

April 25, 2019

ANN ARBOR, Mich. - For men and women affected with antiphospholipid syndrome (APS), blood thinners are the main treatment option.

"Unfortunately, treatment with blood thinners does not prevent all cases of blood clotting in APS," says Jason Knight, M.D., Ph.D., an assistant professor of rheumatology at Michigan Medicine. APS is an autoimmune condition characterized by blood clots in both genders and pregnancy loss in women.

"And those blood thinners do very little to impact the neurologic, hematologic and cardiac complications that regularly affect patients with the condition," he adds.

Knight's lab is currently pursuing the idea that anti-inflammatory treatment might provide a more targeted way to treat APS and give patients better control of the condition with fewer side effects.

"Specifically, we have been interested in the role that neutrophils, the most abundant white blood cells in circulation within the body, play in APS," Knight says. "We've had prior studies demonstrate that neutrophils release sticky, spider web-like structures called neutrophil extracellular traps, also called NETs, that trigger the blood to clot in patients with APS."

Now, Knight and team are building upon that prior work in a new study, published in Nature Communications, that investigated two drugs and their effects on NETs in mice with APS.

"We explored a new strategy for inhibiting those neutrophils, using experimental drug CGS21680 and an approved drug called dipyridamole," says Knight, senior author of the study.

Testing potential treatments

Using mouse models with APS, the research team first administered CGS21680 and found that it reduced the levels of NETs in their blood.

"The drug works by activating adenosine receptors on the neutrophil surface," says Ramadan Ali, Ph.D., a member of Knight's lab and lead author of the study. "Adenosine is best known for its role in energy metabolism, but also has anti-inflammatory effects when released outside of cells. This appears to be a natural pathway for turning off inflammation."

The research team observed that the drug also dramatically reduced the tendency of the mice to form blood clots in large veins.

"Testing this specific drug allowed us to show that activation of adenosine receptors is an effective strategy for preventing NET release in APS, and potentially other contexts as well," Ali says. "We also found that the adenosine-receptor pathway can be exploited to prevent the formation of blood clots."

Because CGS21680 is not approved for use in humans, the research team also decided to test the stroke drug dipyridamole, which has been shown previously to activate adenosine receptors.

"It was very gratifying to see that dipyridamole copied the results of the experimental drug that we began the study with," Ali says. "It reduced both NET release and the tendency of the mice with APS to form clots."

Translating from bench to bedside

While all of the work was preclinical, the research team believes it could be translated to patients with APS.

"This is what's exciting," Knight says. "We have identified a pathway here that is already influenced by a number of drugs approved for use in humans. Beyond dipyridamole, drugs like apremilast, used in patients with psoriasis and psoriatic arthritis, and methotrexate, used to treat rheumatoid arthritis and certain types of cancer, can also modulate adenosine-receptor signaling."

He adds, "Translating these findings to a clinical trial in patients could therefore be very straightforward."

Based on their findings, the research team plans to move forward with a pilot clinical trial in patients with APS.

"We're very motivated to provide safer, more effective and more individualized treatments for patients with APS we see in our clinic," Knight says. "The hope is that by continuing to pursue anti-neutrophil therapeutics, we will be treating APS closer to its source and thereby neutralize all aspects of the condition."
-end-
This study was a multiple-year collaboration across the following authors and their departments at the University of Michigan including: Yogendra Kanthi, M.D. (vascular medicine); David Pinsky, M.D. (cardiology); Paula Bockenstedt, M.D. (hematology); Jose Diaz, M.D. (vascular surgery); and Joan Greve, Ph.D., and Olivia Palmer, Ph.D. (biomedical engineering). Additional authors of the study from Knight's lab include: Alex Gandhi, Srilakshmi Yalavarthi, M.S., Andrew Vreede, M.D., He Meng, M.D., Ph.D., and Shanea Estes, MLI.

The study was funded by NIH-NHLBI (R01HL134846 to Knight) and the lead author (Ali) was supported by NIH-NIAMS through the Michigan Rheumatology training grant (T32AR007080).


Michigan Medicine - University of Michigan

Related Blood Clots Articles:

Researchers find new way to detect blood clots
Researchers in the Department of Biomedical Engineering at Texas A&M University are working on an entirely new way to detect blood clots, especially in pediatric patients.
High rate of blood clots in COVID-19
COVID-19 is associated with a high incidence of venous thromboembolism, blood clots in the venous circulation, according to a study conducted by researchers at Brighton and Sussex Medical School (BSMS), UK.
New tool helps distinguish the cause of blood clots
A new tool using cutting-edge technology is able to distinguish different types of blood clots based on what caused them, according to a study published today in eLife.
Hookah smoke may be associated with increased risk of blood clots
In a new study conducted in mice, researchers found that tobacco smoke from a hookah caused blood to function abnormally and be more likely to clot and quickly form blood clots.
Reducing the risk of blood clots in artificial heart valves
People with mechanical heart valves need blood thinners on a daily basis, because they have a higher risk of blood clots and stroke.
New study finds blood clots more likely in children who receive PICCs
A new study provides convincing evidence that the use of peripherally inserted central catheters (PICCs) to administer medicine and draw blood in children is associated with a significantly increased risk of blood clots (known as venous thromboembolism or VTE) compared with central venous catheters (CVCs) placed directly into the neck or chest.
New study provides insight into the mechanisms of blood clots in cancer patients
Researchers have identified a potential new signaling pathway that may help further the understanding of blood clot formation in cancer patients and ultimately help prevent this complication from occurring.
Cellular senescence is associated with age-related blood clots
Cells that become senescent irrevocably stop dividing under stress, spewing out a mix of inflammatory proteins that lead to chronic inflammation as more and more of the cells accumulate over time.
One in five haematological cancer patients suffer blood clots or bleeding
In the years following haematological cancer, one in five survivors suffer a blood clot or bleeding which requires hospital treatment.
Targeting inflammation to better understand dangerous blood clots
Forty percent of people who develop venous thromboembolism don't know what caused it.
More Blood Clots News and Blood Clots Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Biology Of Sex
Original broadcast date: May 8, 2020. Many of us were taught biological sex is a question of female or male, XX or XY ... but it's far more complicated. This hour, TED speakers explore what determines our sex. Guests on the show include artist Emily Quinn, journalist Molly Webster, neuroscientist Lisa Mosconi, and structural biologist Karissa Sanbonmatsu.
Now Playing: Science for the People

#569 Facing Fear
What do you fear? I mean really fear? Well, ok, maybe right now that's tough. We're living in a new age and definition of fear. But what do we do about it? Eva Holland has faced her fears, including trauma and phobia. She lived to tell the tale and write a book: "Nerve: Adventures in the Science of Fear".
Now Playing: Radiolab

The Wubi Effect
When we think of China today, we think of a technological superpower. From Huweai and 5G to TikTok and viral social media, China is stride for stride with the United States in the world of computing. However, China's technological renaissance almost didn't happen. And for one very basic reason: The Chinese language, with its 70,000 plus characters, couldn't fit on a keyboard.  Today, we tell the story of Professor Wang Yongmin, a hard headed computer programmer who solved this puzzle and laid the foundation for the China we know today. This episode was reported and produced by Simon Adler with reporting assistance from Yang Yang. Special thanks to Martin Howard. You can view his renowned collection of typewriters at: antiquetypewriters.com Support Radiolab today at Radiolab.org/donate.